Chemomab Therapeutics Ltd
chemomab.comWhat Do They Do?
Develops nebokitug, an antibody drug candidate for fibrotic and inflammatory diseases, including primary sclerosing cholangitis and systemic sclerosis.
20-F for FY2025, filed Mar 23, 2026We are a clinical-stage biotechnology company focused on the discovery and development of innovative therapeutics for fibrotic and…View ↗
We have pioneered the therapeutic targeting of CCL24, a chemokine also known as eotaxin-2, which promotes various types of cellular…View ↗
Nebokitug, our lead clinical product candidate, is a first-in-class humanized monoclonal antibody that attenuates the basic function of…View ↗
Our lead product candidate, nebokitug, is a first-in-class humanized monoclonal antibody targeting CCL24 that is being assessed in two…View ↗
How Do They Make Money?
No revenue reported yet.
20-F for FY2025, filed Mar 23, 2026
How Are They Changing?
Drug candidate renamed
The lead antibody had a different name in the earlier report; the latest report calls it nebokitug.
10-K for FY2022, filed Mar 20, 2023 20-F for FY2025, filed Mar 23, 2026We are a clinical-stage biotechnology company focused on the discovery and development of innovative therapeutics for fibrotic and…View ↗
Nebokitug, our lead clinical product candidate, is a first-in-class humanized monoclonal antibody that attenuates the basic function of…View ↗
Our lead product candidate, nebokitug, is a first-in-class humanized monoclonal antibody targeting CCL24 that is being assessed in two…View ↗
PSC program advanced
The earlier report described the PSC study as ongoing; the latest report says it is complete and outlines a planned pivotal trial.
10-K for FY2022, filed Mar 20, 2023 20-F for FY2025, filed Mar 23, 2026CM-101, our lead clinical product candidate, is a first-in-class humanized monoclonal antibody that attenuates the basic function of the…View ↗
SSc study put on hold
The earlier report planned to open a study in SSc; the latest report says initiation is suspended while resources focus on the PSC program.
10-K for FY2022, filed Mar 20, 2023 20-F for FY2025, filed Mar 23, 2026We are also planning to open a Phase 2 clinical trial in SSc about midyear 2023. The trial in SSc, a rare autoimmune rheumatic disease…View ↗
The nebokitug SSc clinical program is Phase 2-ready and we have an open IND in the United States for a Phase 2 clinical trial. However…View ↗
Who Do They Compete With?
Competes with Dr. Falk Pharma, Ipsen Pharmaceuticals, Mirum Pharmaceutical, Amgen, Merck, GSK, Boehringer Ingelheim, and AstraZeneca
20-F for FY2025, filed Mar 23, 2026There are currently no FDA-approved therapies for the treatment of PSC. Companies currently developing product candidates in Phase 3…View ↗
Loading...
